All In Biotech

Drug Trial Radar · NCT06979609

Secondary Prevention of Clostridioides Difficile Using Vancomycin

Secondary Prophylaxis of Recurrent Clostridioides Difficile Infections During Systemic Antibiotics With Vancomycin: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Nov 1, 2025

Primary completion

Oct 1, 2028

Study completion Oct 1, 2029

Sponsor

Sponsor type
Academic, hospital or other
First posted
May 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Re-exposure to systemic antibiotics (i.e., antibiotics absorbed into the bloodstream) is common after a Clostridioides difficile infection (CDI) and is the strongest risk factor for a recurrent episode. Oral vancomycin to prevent a recurrence during antibiotic re-exposure may reduce this risk but the data supporting this practice are limited. The aim of this trial is: 1\) Does oral vancomycin prophylaxis prevent CDI recurrences in patients with recent CDI (within 120 days) and who are re-exposed to systemic antibiotics? The trial will compare oral vancomycin to placebo. Participants will: * Take the study drug (either vancomycin or placebo) twice daily for the duration of systemic antibiotics plus once daily for 7 days after completion of systemic antibiotics. * Attend an in-person or over the phone follow-up at day 56 * Respond to weekly electronic questionnaires

Conditions

  • Clostridioides Difficile Infection
  • Clostridioides Difficile Infection Recurrence
  • Clostridoides Difficile Associated Disease

Interventions

  • Oral Vancomycin ProphylaxisDrug

    125mg PO BID for the duration of antibiotic re-exposure + 125mg PO QD for 7 days

  • PlaceboDrug

    2 capsules PO BID for the duration of antibiotic re-exposure + 1 capsule PO QD x 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CDI RecurrenceTime frame: 56 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • McGill University Health Centre

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.